Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atai Life Sciences N.V. (NQ: ATAI )

1.170 +0.020 (+1.74%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 936,430
Open 1.170
Bid (Size) 1.170 (7)
Ask (Size) 1.180 (115)
Prev. Close 1.150
Today's Range 1.110 - 1.170
52wk Range 1.025 - 3.560
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
Defense Dept. Funds Ketamine Study For PTSD Treatment  
Via Benzinga
November Recap: Psychedelic Drug Stocks Index Driven 30% Higher By Incannex
The 5 constituents in the Psychedelic Drug Stocks Index had declined 46.5% over the past 3 months but jumped 30% in November. 
Via Talk Markets

Performance

YTD
-55.85%
-55.85%
1 Month
-11.36%
-11.36%
3 Month
-18.75%
-18.75%
6 Month
-37.43%
-37.43%
1 Year
-62.97%
-62.97%

More News

Read More
Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More
Via Benzinga
Topics Cannabis
Exposures Cannabis
GH Research, Compass Pathways Among Top Psychedelic Movers Of Today
Via Benzinga
GH Research Drags Down Psychedelic Drug Stocks Index By 7%
Via Talk Markets
Insiders Buying Taysha Gene Therapies And 3 Other Stocks Under $2
Via Benzinga
Topics Stocks
Exposures US Equities
Atai Life Sciences' Q3 Earnings: Near $20M Burned QoQ, Says Funding 'Sufficient' To Streamline 2026
Via Benzinga
atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights
From atai Life Sciences
Via GlobeNewswire
Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Psychedelic Compound-Based R&D Stocks Not For The Faint Of Heart
Via Talk Markets
Psyched: DEA's Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More
Via Benzinga
Topics Economy
Exposures Interest Rates
Favorable Q3 Financial Reports Lift Largest Psychedelic Sector Stocks By 22%
Via Talk Markets
Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted
Via Benzinga
Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More
Via Benzinga
Exposures Product Safety
Psychedelic-Compound-Based Drug Stocks Continue To Fall
Via Talk Markets
Psyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More
Via Benzinga
atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit
From atai Life Sciences
Via GlobeNewswire
Major Psychedelic Drug Stocks Continued To Decline This Week
Via Talk Markets
Atai Life Sciences Completes Phase 1 Clinical Study Of Oral Film DMT Formulation
Via Benzinga
atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants
From atai Life Sciences
Via GlobeNewswire
Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More
Via Benzinga
September Summary: Largest Psychedelic Drug Stocks Dropped 14%
Via Talk Markets
Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More
Via Benzinga
Topics Economy
Exposures Interest Rates
Psychedelic Drug Stocks Dragged Down By 83% Collapse In SEEL Stock Price
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.